July 31, 2026

Postsurgical Ensartinib in ALK-Positive NSCLC

Adjuvant ensartinib may represent a new therapeutic strategy in completely resected disease.

MDSpire News

July 30, 2026

FDA Monthly Preview: Key August Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

July 30, 2026

Texas Practice Resolves Controlled Substances Act Allegations

Settlement addresses alleged record-keeping and Schedule II controlled substance prescription violations.

MDSpire News

July 29, 2026

FDA Approves Low-Estrogen Contraceptive Patch

Phase 3 data showed contraceptive efficacy, 1.3% complete patch detachment, and decreased rates of unscheduled bleeding or spotting through cycle 13.

MDSpire News

July 27, 2026

Colorectal Cancer Screening Blood Test Approved by FDA

The blood-based assay demonstrated 81% sensitivity for colorectal cancer in the PREEMPT CRC study.

MDSpire News

July 27, 2026

FDA Approves Centanafadine for ADHD

The first approved norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD demonstrated symptom improvements as early as week 1 in phase 3 trials.

MDSpire News

July 24, 2026

FDA Approves Acetaminophen/Naproxen Sodium

The fixed-dose combination product combines acetaminophen with naproxen sodium and is labeled to provide up to 12 hours of temporary pain relief.

MDSpire News

July 24, 2026

FDA Approves Furoscix ReadyFlow

Clinical data demonstrated achievement of the primary pharmacokinetic endpoint, with urine output and sodium and potassium excretion comparable with those observed with intravenous furosemide, according to MannKind.

MDSpire News

July 23, 2026

FDA Approves Zidesamtinib for ROS1 Lung Cancer

Phase 1/2 ARROS-1 data showed a 44% objective response rate, with most responses ongoing at 6 months.

MDSpire News

July 23, 2026

Weekly HIV Therapy Meets Primary Endpoint

Patients who switched from daily antiretroviral therapy maintained virologic suppression in two phase 3 trials.

MDSpire News